// App-Quantinova.ai

9038 : Health-related quality of life for pembrolizumab (pembro) plus ipilimumab (ipi) versus pembro plus placebo in patients with metastatic NSCLC with PD-L1 tumor proportion score ≥ 50%: KEYNOTE-598.

Researchers

Presenter

  • Mehmet Nahit Sendur

Principal Investigators

  • Delvys Rodriguez-Abreu

  • Keunchil Park

  • Dae Ho Lee

  • Irfan Cicin

  • Perran Fulden Yumuk

  • Francisco J Orlandi

  • Ticiana A. Leal

  • Olivier Molinier

  • Nopadol Soparattanapaisarn

  • Adrian Langleben

  • Raffaele Califano

  • Balazs Medgyasszay

  • Te-Chun Hsia

  • Gregory Alan Otterson

  • Lu Xu

  • Thomas A. Burke

  • Ayman Samkari

  • Michael J. Boyer

Medical Centers

  • Ankara Yıldırım Beyazıt University, Faculty of Medicine and Ankara City Hospital, Ankara, Turkey

  • LungenClinic, Airway Research Center North, German Center for Lung Research, Grosshansdorf, Germany

  • Complejo Hospitalario Universitario Insular Materno-Infantil de Gran Canaria, Universidad de Las Palmas de Gran Canaria, Las Palmas De Gran Canaria, Spain

  • Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea

  • Asan Medical Center, Seoul, South Korea

  • Trakya University, Edirne, Turkey

  • Marmara University School of Medicine, Istanbul, Turkey

  • Orlandi-Oncología, Providencia, Chile

  • University of Wisconsin Carbone Cancer Center, Madison, WI, Hospital of Le Mans, Le Mans, France

  • Mahidol University, Siriraj Hospital, Bangkok, Thailand

  • St. Mary’s Hospital–ODIM, McGill University Department of Oncology, Montreal, QC, Canada

  • Medical Oncology Department, The Christie NHS Foundation Trust, Division of Cancer Sciences, University of Manchester, Manchester, United Kingdom

  • Veszprém Megyei Tüdőgyógyintézet Farkasgyepű, Farkasgyepű, Hungary

  • China Medical University and China Medical University Hospital, Taichung, Taiwan, Ohio State University-James Comprehensive Cancer Center, Columbus, OH, Merck & Co., Inc., Kenilworth, NJ, Chris O’Brien Lifehouse, Camperdown, NSW, Australia

Locations

  • Turkey

  • Germany

  • Spain

  • Chile

  • France

  • Thailand

  • Canada

  • United Kingdom

  • Hungary

  • Australia

Companies

  • N/A

Study Components

Therapeutic Area

  • Pulmonary/Respiratory Diseases

  • Oncology (ONC)

  • Cardiovascular (CVS)

Disease

  • Angina

  • Dyspnea

  • Non Small Cell Lung cancer

Biomarkers

  • Programmed death-ligand 1

  • Tissue polypeptide-specific antigen

Drug/Treatment

  • Pembrolizumab

  • Ipilimumab

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

Phase

  • III

Study Id's

  • NCT03302234

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved